As FDA Review Looms, Drug Cos. Defend Vytorin Study

Law360, New York (January 24, 2008, 12:00 AM EST) -- Merck & Co. and Schering-Plough Corp. continued to defend a controversial study of their Vytorin and Zetia cholesterol treatments Friday on the heels of the U.S. Food and Drug Administration announcing that it will review the study once it receives the final results.

The FDA said that it will take about six months to fully evaluate the data once it receives the final so-called Enhance study.

“After reviewing the data from the Enhance study, and considering all other available information about the link between LDL (bad...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.